ClinicalTrials.gg
CompletedNCT01012219Updated Nov 2, 2015Results posted

A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)

A Phase 1 interventional study of niacin (+) laropiprant and Comparator: aspirin in Primary Hypercholesterolemia and Mixed Hyperlipidemia, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-11-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Hyperlipoproteinemia Type II by Merck & Co., Inc — 1 open to participants now, 1 under way, 1 of them phase 3. Hyperlipoproteinemia Type II · Merck & Co., Inc.

Enrollment
15th of 17
36 · median 381
Started
2009
with 1 other
Phase 1
2 of 17
none open now
Registered
9th of 17
by date

Among the 17 studies in Hyperlipoproteinemia Type II by Merck & Co., Inc, this one is the 15th largest by enrollment, is one of 2 that started in 2009, is one of 2 in phase 1, and was the 9th registered.

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

1 of the 17 studies in Hyperlipoproteinemia Type II by Merck & Co., Inc is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Hyperlipoproteinemia Type II by Merck & Co., Inc, or all of them as a file.
02

Study summary

This is a 3-period study. Periods 1 and 2 will evaluate the effects of multiple doses of laropiprant on the antiplatelet effects of clopidogrel and aspirin administered in combination in participants with primary hypercholesterolemia or mixed dyslipidemia. Period 3 will be open-label and will evaluate single dose pharmacokinetics of nicotinic acid and laropiprant components of Tredaptive.

03

Conditions studied

  • Primary Hypercholesterolemia
  • Mixed Hyperlipidemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has primary hypercholesterolemia or mixed dyslipidemia (high cholesterol)
  • Participant is a non-smoker

Exclusion criteria

Exclusion Criteria:

  • Participant has a history of chronic seizures
  • Participant has a history of cancer
  • Participant has a history of stomach or intestinal ulcers or any history of GI bleeding
  • Participant has had major surgery, donated blood or participated in another study in the past 4 weeks
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Period 1

    In Periods 1 and 2 each participant will receive one of the following treatments in a randomized crossover fashion: Treatment A (aspirin 81 mg, clopidogrel 75 mg and laropiprant 40 mg once daily for 7 days) or Treatment B (aspirin 81 mg, clopidogrel 75 mg and placebo to laropiprant 40 mg once daily for 7 days).

    Drug: Comparator: aspirin · Drug: Comparator: clopidogrel · Drug: Comparator: laropiprant · Drug: Comparator: placebo

  • Experimental
    Period 2

    In Periods 1 and 2 each participant will receive one of the following treatments in a randomized crossover fashion: Treatment A (aspirin 81 mg, clopidogrel 75 mg and laropiprant 40 mg once daily for 7 days) or Treatment B (aspirin 81 mg, clopidogrel 75 mg and placebo to laropiprant 40 mg once daily for 7 days).

    Drug: Comparator: aspirin · Drug: Comparator: clopidogrel · Drug: Comparator: laropiprant · Drug: Comparator: placebo

  • Experimental
    Period 3

    Drug: niacin (+) laropiprant

Interventions

  • Drugniacin (+) laropiprant

    Drug pages: Niacin · MK-0524

    open-label, single dose Tredaptive (1000mg ER niacin/ 20mg laropiprant) 2 oral tablets

    Also known as: Tredaptive

  • 81 mg oral tablet once daily for 7 days

  • 75 mg oral tablet once daily for 7 days

  • 40 mg oral tablet once daily for 7 days

  • DrugComparator: placebo

    placebo oral tablet once daily for 7 days

06

What researchers measure

Primary outcomes

  1. Cutaneous Bleeding Time (BT)

    Cutaneous bleeding Time (BT) on Day 8 after daily administration of laropiprant with aspirin and clopidogrel for 7 days versus BT on Day 8 after daily administration of placebo with aspirin and clopidogrel for 7 days. The model used included treatment, period and sequence as fixed effect variables and subjects as the random effect variable. Period 3 was not analyzed as bleeding time was not an objective for this part of the study.

    Time frame: Day 8

07

Results

Posted Apr 18, 2011

Participant flow

Period 1
Participant flow — Period 1
MilestoneAll Participants
Started36
Completed35
Not completed1
Withdrew: Withdrawal by subject1
Period 2
Participant flow — Period 2
MilestoneAll Participants
Started35
Completed34
Not completed1
Withdrew: Withdrawal by subject1
Period 3
Participant flow — Period 3
MilestoneAll Participants
Started20
Completed20
Not completed0

Outcome measures

PrimaryCutaneous Bleeding Time (BT)

Cutaneous bleeding Time (BT) on Day 8 after daily administration of laropiprant with aspirin and clopidogrel for 7 days versus BT on Day 8 after daily administration of placebo with aspirin and clopidogrel for 7 days. The model used included treatment, period and sequence as fixed effect variables and subjects as the random effect variable. Period 3 was not analyzed as bleeding time was not an objective for this part of the study.

Time frame:
Day 8
Reported as:
Least squares mean · Seconds
Cutaneous Bleeding Time (BT)
SecondsClopidogrel + Aspirin +LaropiprantClopidogrel + Aspirin
Cutaneous Bleeding Time (BT)478 (381 to 599)389 (309 to 490)
Statistical analysis
  • Clopidogrel + Aspirin +Laropiprant vs Clopidogrel + Aspirin · Geometric least-squares mean ratio: 1.23 · 90% CI 0.96 to 1.56

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Laropiprant + Clopidrogel + Aspirin—0/36 (0%)24/36 (66.7%)
Clopidogrel + Aspirin—0/36 (0%)23/36 (63.9%)
Laropiprant + Niacin—0/20 (0%)20/20 (100%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventLaropiprant + Clopidrogel + AspirinClopidogrel + AspirinLaropiprant + Niacin
VasodilationVascular disorders0/360/3619/20
HeadacheNervous system disorders5/364/364/20
EcchymosisSkin and subcutaneous tissue disorders7/364/360/20
Vessel puncture site haemorrhageGeneral disorders6/363/361/20
MyalgiaMusculoskeletal and connective tissue disorders2/364/360/20
NauseaGastrointestinal disorders0/361/362/20
DizzinessNervous system disorders1/362/362/20
Back painMusculoskeletal and connective tissue disorders3/362/360/20
Pain in extremityMusculoskeletal and connective tissue disorders3/361/360/20
EpistaxisRespiratory, thoracic and mediastinal disorders3/363/360/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Participants
Mean55.0 (24 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female16
Male20
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • De Kam PJ, Luo WL, Wenning L, Ratcliffe L, Sisk CM, Royalty J, Radziszewski W, Wagner JA, Lai E. The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin. Platelets. 2014;25(7):480-7. doi: 10.3109/09537104.2013.836747. Epub 2013 Nov 8. PubMed 24206527 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Mar 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2009
First posted
Nov 11, 2009
Start
Nov 2009
Primary completionActual
Mar 2010
CompletionActual
Apr 2010
Results first posted
Apr 18, 2011
Last update
Nov 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01012219
Responsible party
Sponsor
First posted
Nov 11, 2009
Start date
Nov 2009
Primary completion
Mar 2010
Completion
Apr 2010
Results posted
Apr 18, 2011
Last update
Nov 2, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Niacin · MK-0524 · Aspirin · Clopidogrel

Start the discussion